|
市場調查報告書
糖尿病市場：2015年為止的預測
Diabetes Market Forecast to 2015
|
糖尿病市場：2015年為止的預測 是由出版商Cutting Edge Information在2009年12月所出版的。
這份英文市場調查報告書包含324 Pages 價格從美金9995起跳。
本研究報告詳細分析糖尿病市場現況，並提供廠牌藥與製藥公司動向、市佔比率、投資回收率、品牌策略等情報，內容摘記如下。
糖尿病市場主要動向
糖尿病廠牌藥檔案
- 胰島素
- SU藥物
- Meglitinide
- thiazolidinediones
- DPP-4抑制劑
- 類GLP-1
- SGLT2抑制劑
- 新型糖尿病治療藥
- 糖尿病併發症治療
製藥公司檔案
- Novo Nordisk
- Sanofi-Aventis
- 武田藥品工業
- Eli Lilly
- Merck
- GlaxoSmithKline
- Amylin
- Bristol-Myers Squibb
- Roche
- Boehringer Ingelheim
未來的糖尿病調査
- 糖尿病預防
- 胰島素給藥的改善
- 解讀糖尿病圖譜
- 胰島素循環的停止
- 糖尿病的消滅
醫師對糖尿病市場的看法
從産業界看市場展望
- 心血管疾病發展問題
- 處方者、新興治療法、未滿足需求
- 歐洲市場
圖表
Abstract
Comprehensive Diabetes Forecast
Gain instant access to the most up-to-date information on the diabetes market.
Scour in-depth profiles of brands and diabetes drug makers to target and seize
market share, optimize return on investment, prove the value of your assets,
and set proactive brand strategies.
In addition to market forecasts, you' ll find primary data from physicians
worldwide as well as industry leaders in R&D and marketing. Their input
provides knowledgeable, fresh insights on emerging treatments and unmet needs
in the diabetes space.
Get accurate, honest market outlooks
Save money and valuable time with sales projections, patent information and
clinical data - all in context, so you can compare brands, classes and
companies.
Answer critical questions about your diabetes portfolio:
- Are you entering the diabetes market - or expanding your current portfolio?
- How does your developing drug compare to brands on the market? Does your
drug stand a chance?
- Are you working on another DPP-4 inhibitor or GLP-1 analog - and ignoring
a market push toward novel therapies?
- Have you been hit by the FDA' s cardiovascular guidelines? Are you
adequately prepared for regulatory review?
- Are you trying to out-license a diabetes product?
- How will your early-stage diabetes compound fare in tomorrow' s market? Is
there room for your drug, too?
Report Statistics
- 324 Pages
- 45 Diabetes Product Franchises
- 30+ Companies
- 10 Company Portfolio Profiles
Table of Contents
Key Trends in the Diabetes Market
- Methodology and Definitions
Diabetes Brand Profiles
- Insulins
- Novolin (insulin regular)
- Humulin (insulin recombinant)
- Novolog (insulin aspart)
- Humalog (insulin lispro)
- Apidra (insulin glulisine)
- Lantus (insulin glargine)
- Levemir (insulin detemir)
- Afrezza/Technosphere (insulin human inhalation powder)
- VIAject (prandial insulin)
- Novel Insulins
- Meglitinides
- Prandin Franchise (repaglinide)
- Thiazolidinediones
- Avandia Franchise (rosiglitazone)
- Actos Franchise (pioglitazone)
- DPP-4 Inhibitors
- Januvia Franchise (sitagliptin)
- Galvus Franchise(vildagliptin)
- Onglyza (saxagliptin)
- Ondero (linagliptin)
- Alogliptin
- Dutogliptin
GLP-1 Analogs
- Byetta (exenatide)
- Victoza (liraglutide)
- Syncria (albiglutide)
- Lixisenatide/AVE0010
- Taspoglutide
- LY2189265
SGLT2 Inhibitors
- Novel Antidiabetics
- Symlin (pramlintide)
- Qnexa (phentermine + topiramate)
- Otelixizumab/TRX4
- Teplizumab
- Ilaris (canakinumab)
- TT-223
- Prochymal (mesenchymal stem cells)
- Therapies for Complications Due to Diabetes
- Avapro (irbesartan)
- Cozaar (losartan)
- Cymbalta (duloxetine)
- Lyrica (pregabalin)
- Radiprodil/RGH-896
- Lucentis (ranibizumab)
- PF-4523655
- Zyvox (linezolid)
Drug Manufacturer Profiles
The Future of Diabetes Research
- Preventing the Onset of Diabetes
- Perfecting Insulin Delivery
- Interpreting the Diabetes Map
Physician Perspectives on the Diabetes Market
- Treatments and Unmet Needs
Market Perspectives From the Industry
- Cardiovascular Development Challenges
- Prescibers, Emerging Treatments and Unmet Needs
CHARTS AND GRAPHICS
Key Trends in the Diabetes Market
- Table E.1: Blockbuster Insulins
- Table E.2: Blockbuster Non-Insulin Antidiabetics
- Table E.3: Investigational Brands with Future Blockbuster Potential
- Figure E.1: Insulin Sales, by Type (in Millions)
- Figure E.2: Profiled Established Insulins
- Figure E.3: Profiled Novel Insulins
- Figure E.4: Developing Noninsulin Sales, by Class (in Millions)
- Figure E.5: Profiled DPP-4 Inhibitors
- Figure E.6: Profiled GLP-1 Analogs
- Figure E.7: Profiled SGLT2 Inhibitor
- Figure E.8: Profiled Novel Therapies
- Figure E.9: Established Antidiabetics Sales, by Class (in Millions)
- Figure E.10: Profiled Thiazolidinediones
- Figure E.11: Profiled Sulfonylurea
- Figure E.12: Profiled Meglitinide
- Figure E.13: Profiled Drugs Treading Diabetic Complications
- Table E.4: Top Companies in the Antidiabetic Market
- Figure E.14: Current DiabetesMarket Split
- Figure E.15: Projected 2015 DiabetesMarket Split
Diabetes Brand Profiles
- Insulins
- Profiled Established Insulins
- Profiled Novel Insulins
- Insulin Sales: 2006-2015
- Novolin (insulin regular)
- Materiality to Novo Nordisk: 2009
- Materiality to Novo Nordisk: 2015
- Novolin Sales: 2006-2015
- Humulin (insulin recombinant)
- Materiality to Eli Lilly: 2009
- Materiality to Eli Lilly: 2015
- Humulin Sales: 2006-2015
- Novolog (insulin aspart)
- Materiality to Novo Nordisk: 2009
- Materiality to Novo Nordisk: 2015
- Novolog Sales: 2006-2015
- Humalog (insulin lispro)
- Materiality to Eli Lilly: 2009
- Materiality to Eli Lilly: 2015
- Humalog Sales: 2006-2015
- Apidra (insulin glulisine)
- Materiality to Sanofi-Aventis: 2009
- Materiality to Sanofi-Aventis: 2015
- Lantus Sales: 2006-2015
- Afrezza/Technosphere (insulin human inhalation powder)
- Materiality toMannKind: 2010
- Materiality toMannKind: 2015
- Afrezza Sales: 2010-2015
- VIAject (prandial insulin)
- Materiality to Biodel: 2011
- Materiality to Biodel: 2015
- VIAject Sales: 2011-2015
- Sulfonylureas
- Profiled Sulfonylurea
- Sulfonylurea Sales: 2006-2015
- Amaryl(glimepiride)
- Materiality to Sanofi-Aventis: 2009
- Materiality to Sanofi-Aventis: 2015
- Amaryl Sales: 2006-2015
- Meglitinides
- Profiled Meglitinides
- Meglitinide Sales: 2006-2015
- Prandin Franchise (repaglinide)
- Materiality to Novo Nordisk: 2009
- Materiality to Novo Nordisk: 2015
- Prandin Sales: 2006-2015
- Thiazolidinediones
- Profiled Thiazolidinediones
- Thiazolidinediones Sales: 2006-2015
- Avandia Franchise (rosiglitazone)
- Materiality to GlaxoSmithKline: 2009
- Materiality to GlaxoSmithKline: 2015
- Avandia Sales: 2006-2015
- Actos Franchise (pioglitazone)
- Materiality to Takeda: 2009
- Materiality to Eli Lilly: 2009
- Materiality to Takeda: 2015
- Materiality to Eli Lilly: 2015
- Actos Sales: 2006-2015
- DPP-4 Inhibitors
- DPP-4 Inhibitor Sales: 2006-2015
- Januvia Franchise (sitagliptin)
- Materiality toMerck: 2009
- Materiality toMerck: 2015
- Januvia Sales: 2006-2015
- Galvus Franchise(vildagliptin)
- Materiality to Galvus: 2009
- Materiality to Galvus: 2015
- Galvus Sales: 2006-2015
- Onglyza (saxagliptin)
- Materiality to BMS: 2009
- Materiality to AstraZeneca: 2009
- Materiality to BMS: 2015
- Materiality to AstraZeneca: 2015
- Onglyza Sales: 2009-2015
- Ondero (linagliptin)
- Materiality to Boehringer Ingelheim: 2011
- Materiality to Boehringer Ingelheim: 2015
- Ondero Sales: 2011-2015
- Alogliptin
- Materiality to Takeda: 2013
- Materiality to Takeda: 2015
- Alogliptin Sales: 2013-2015
- Dutogliptin
- Materiality to Forest Labs: 2013
- Materiality to Forest Labs: 2015
- Dutogliptin Sales: 2013-2015
- GLP-1 Analog
- Profiled GLP-1 Analogs
- GLP-1 Analog Sales: 2006-2015
- Byetta (exenatide)
- Materiality to Amylin: 2009
- Materiality to Amylin: 2015
- Materiality to Eli Lilly: 2009
- Materiality to Eli Lilly: 2015
- Materiality to Alkermes: 2015
- Byetta Sales: 2006-2015
- Victoza (liraglutide)
- Materiality to Novo Nordisk: 2009
- Materiality to Novo Nordisk: 2015
- Victoza Sales: 2009-2015
- Syncria (albiglutide)
- Materiality to GSK: 2012
- Materiality to GSK: 2015
- Syncria Sales: 2012-2015
- Lixisenatide/AVE0010
- Materiality to Sanofi-Aventis: 2011
- Materiality to Sanofi-Aventis: 2015
- Lixisenatide Sales: 2011-2015
- Taspoglutide
- Materiality to Roche: 2011
- Materiality to Roche: 2015
- Taspoglutide Sales: 2011-2015
- LY2189265
- Materiality to Eli Lilly: 2012
- Materiality to Eli Lilly: 2015
- LY2189265 Sales: 2012-2015
- SGLT2 Inhibitors
- Profiled SGLT2 Inhibitors
- SGLT2 Inhibitor Sales: 2012-2015
- Dapagliflozin
- Materiality to AstraZeneca: 2012
- Materiality to BMS: 2012
- Materiality to AstraZeneca: 2015
- Materiality to BMS: 2015
- Dapagliflozin Sales: 2012-2015
- Novel Antidiabetics
- Novel Therapies Sales: 2006-2015
- Symlin (pramlintide)
- Materiality to Amylin: 2009
- Materiality to Amylin: 2015
- Symlin Sales: 2006-2015
- Qnexa (phentermine + topiramate)
- Materiality to Vivus: 2010
- Materiality to Vivus: 2015
- Qnexa Sales: 2010-2015
- Otelixizumab/TRX4
- Materiality to GSK: 2012
- Materiality to GSK: 2015
- Otelixizumab Sales: 2012-2015
- Teplizumab
- Materiality to Eli Lilly: 2012
- Materiality to Eli Lilly: 2015
- Teplizumab Sales: 2012-2015
- Ilaris (canakinumab)
- Materiality to Novartis: 2009
- Materiality to Novartis: 2015
- Ilaris Sales: 2009-2015
- TT-223
- Materiality to TT-223: 2012
- Materiality to TT-223: 2015
- TT-223 Sales: 2012-2015
- Prochymal (mesenchymal stemcells)
- Materiality to Genzyme: 2011
- Materiality to Genzyme: 2015
- Prochymal Sales: 2011-2015
- Therapies for Complications Due to Diabetes
- Profiled Diabetic Complications
- Avapro (irbesartan)
- Materiality to BMS: 2009
- Materiality to Sanofi-Aventis: 2009
- Materiality to BMS: 2015
- Materiality to Sanofi-Aventis: 2015
- Avapro Sales: 2006-2015
- Cozaar (losartan)
- Materiality toMerck: 2009
- Materiality toMerck: 2015
- Cozaar Sales: 2006-2015
- Cymbalta (duloxetine)
- Materiality to Eli Lilly: 2009
- Materiality to Eli Lilly: 2015
- Cymbalta Sales: 2006-2015
- Lyrica (pregabalin)
- Materiality to Pfizer: 2009
- Materiality to Pfizer: 2015
- Lyrica Sales: 2006-2015
- Radiprodil/RGH-896
- Materiality to Forest Labs: 2013
- Materiality to Forest Labs: 2015
- Radiprodil Sales: 2013-2015
- Lucentis (ranibizumab)
- Materiality to Novartis: 2009
- Materiality to Roche: 2009
- Materiality to Novartis: 2015
- Materiality to Roche: 2015
- Lucentis Sales: 2006-2015
- PF-4523655
- Materiality to Pfizer: 2013
- Materiality to Pfizer: 2015
- PF-4523655 Sales: 2013-2015
- Zyvox (linezolid)
- Materiality to Pfizer: 2013
- Materiality to Pfizer: 2015
- Zyvox Sales: 2006-2015
Drug Manufacturer Profiles
- Novo Nordisk
- Novo Nordisk' s Diabetes Revenue
- Novo Nordisk' s 2009 Market Share
- Novo Nordisk' s Percentage Diabetes Revenue Growth Through 2015
- Novo Nordisk' s Diabetes Product Pipeline
- Sanofi-Aventis
- Sanofi-Aventis' 2009 Diabetes Revenue 2009
- Sanofi-Aventis' 2009 Market Share
- Sanofi-Aventis' Percentage Diabetes Revenue Growth Through 2015
- Sanofi-Aventis' Diabetes Product Pipeline
- Takeda
- Takeda' s Diabetes Revenue 2009
- Takeda' s 2009 Market Share
- Takeda' s Percentage Diabetes Revenue Growth Through 2015
- Takeda' s Diabetes Product Pipeline
- Eli Lilly
- Eli Lilly' s Diabetes Revenue 2009
- Eli Lilly' s 2009 Market Share
- Eli Lilly' s Percentage Diabetes Revenue Growth Through 2015
- Eli Lilly' s Diabetes Product Pipeline
- Merck
- Merck' s Diabetes Revenue 2009
- Merck' s 2009 Market Share
- Merck' s Percentage Diabetes Revenue Growth Through 2015
- Merck' s Diabetes Product Pipeline
- GlaxoSmithKline
- GSK' s Diabetes Revenue 2009
- GSK' s 2009 Market Share
- GSK' s Percentage Diabetes Revenue Growth Through 2015
- GSK' s Diabetes Product Pipeline
- Amylin
- Amylin' s Diabetes Revenue 2009
- Amylin' s 2009 Market Share
- Amylin' s Percentage Diabetes Revenue Growth Through 2015
- Amylin' s Diabetes Product Pipeline
- Bristol-Myers Squibb
- BMS' s Market Share 2015
- Bristol-Myers Squibb' s Diabetes Product Pipeline
- Roche
- Roche' s Market Share 2015
- Roche' s Diabetes Product Pipeline
- Boehringer Ingelheim
- Boehringer Ingelheim' s Market Share 2015
- Boehringer Ingelheim' s Diabetes Product Pipeline
The Future of Diabetes Research
Physician Perspectives on the Diabetes Market
- Figure 4.1: Percentage Breakout of Responding Physicians' Institutions
- Figure 4.2: Percentage Breakout of Responding Physicians' and
Institutions' Region
- Figure 4.3: Best Type 1 Diabetes Therapy Treatments and Unmet Needs
- Figure 4.4: Best Type 2 Diabetes Therapy
- Figure 4.5: Percentage Breakout ofGreatest Unmet Needs for Type 1 Diabetes
- Figure 4.6: Percentage Breakout ofGreatest New Science Needs for Type 1
Diabetes
- Figure 4.7: Percentage Breakout of Unmet Adherence Issues for Type 1
Diabetes
- Figure 4.8: Percentage Breakout ofGreatest Unmet Needs for Type 2 Diabetes
- Figure 4.9: Percentage Breakout ofGreatest New Science Needs for Type 2
Diabetes
- Figure 4.10: Percentage Breakout of Unmet Adherence Issues for Type 2
Diabetes
- Figure 4.11: Percentage Breakout of Greatest Unmet Needs for Complications
in Type 2 Diabetes
- Figure 4.12: Responding PhysiciansWho Work with Cardiologists as Part of
Normal Treatment Regimen
- Figure 4.13: Physicians' Response to Current Discussion of Cardiovascular
Risks
- Figure 4.14: Type 1 Greatest New Science Needs by Region
- Unmet Needs by Region
- Figure 4.15: Type 1 New Device Needs by Region
- Figure 4.16: Type 2 Greatest New Science Needs by Region
- Figure 4.17: Type 1 Greatest Adherence Issues by Region
- Figure 4.18: Type 2 Greatest Adherence Issues by Region
- Figure 4.19: Type 1 Complications Concerns by Region
- Figure 4.20: Type 2 Complications Concerns by Region
|
